Company intelligence / Profile preview

Cognet

Cambridge / Waltham, Massachusetts, United States of Americacogentbio.com ↗

Ownership: Private
Employees: ~164
Development stage: Other

Overview

Cogent Biosciences is a clinical-stage biotechnology company developing precision therapies for genetically defined diseases. Its lead candidate, bezuclastinib, targets KIT mutations and is being evaluated in systemic mastocytosis and GIST. The company also has monoclonal antibody and small molecule programs targeting other genetically driven conditions[3][4].

Therapeutic areas: OncologyInfectious DiseasesHematology
Modalities: Monoclonal antibodySmall molecule
Industry: Biotech

Partnerships

Collaborations with research institutions and companies to expand pipeline capabilities

Beyond the preview

Go deeper on Cognet.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Cognet.

Explore the full profile